# ELVITEGRAVIR, COBICISTAT, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE
> **ANDA218575** · Abbreviated New Drug Application (Generic) · Sponsor: APOTEX INC · Approved 2026-02-09
## Drug
- **FDA Application Number:** ANDA218575
- **Application type:** Abbreviated New Drug Application (Generic)
- **Brand name:** ELVITEGRAVIR, COBICISTAT, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE
- **Generic name:** Elvitegravir, Cobicistat, Emtricitabine And Tenofovir Alafenamide
- **Active ingredients:** ELVITEGRAVIR, COBICISTAT, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE
- **Dosage form:** TABLET
- **Route:** —
- **Marketing status:** None (Tentative Approval)
- **Sponsor:** APOTEX INC
- **First approval:** 2026-02-09
## Source
- [Drugs@FDA application overview](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218575)
---
*MORVS · CC0 1.0*